Aggregated price index with volume information
Summary:
- Health Insurers stocks down 0.9% on average while median return down 0.7% in a day
- Health Insurers stocks up 0.4% on average while median return up 1.0% in a week
- Health Insurers stocks down 5.6% on average while median return down 4.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
Related ETFs (click on ticker for stock detail page)
- 1M winners are : Winners for past month are $RXD 9.4%, $UNH 0.3%
- 1M losers are : Losers for past month are $HUM -10.6%, $CURE -13.1%, $CVS -15.1%, $MOH -15.8%, $EHTH -23.9%
- 1W winners are : Winners for past week are $UHS 7.5%, $CURE 2.7%, $CNC 2.6%, $RXL 2.1%, $HQH 1.7%
- 1W losers are : Losers for past week are $RXD -2.0%, $MOH -2.4%, $CVS -3.0%, $HUM -4.1%, $EHTH -4.1%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 32.0%, for the past 3 months is 24.0%
In the past month for a 5 days rolling window, the highest corrrelation is 47.3%, the lowest correlation is 7.9%, the latest correlation is 24.4%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 99.5% between CURE and XLV
The lowest correlation is -99.7% between RXD and RXL
Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday. Cigna said it will stock high- and low-concentration biosimilar versions of Humira from drugmakers including Boehringer Ingelheim, Teva and Alvotech at its Accredo pharmacy.
In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira® biosimilar available for $0 out of pocket for eligible patients of its specialty pharmacy Accredo beginning this June. The high- and low-concentration interchangeable biosimilar will be produced for Evernorth's affiliate private label pharmaceutical distributor, Quallent Pharmaceuticals, through agreements with mu
Community Health's (CYH) first-quarter results benefit from improved occupancy and reimbursement rates. However, declining admissions partially offset the positives.
Molina Healthcare's (MOH) Q1 results reflect strong premium revenue growth. It continues to estimate adjusted EPS at a minimum of $23.50 for 2024.
Humana Inc. (NYSE:HUM) Q1 2024 Earnings Call Transcript April 24, 2024 Humana Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $6.02. HUM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for […]
Universal Health's (UHS) first-quarter results benefit from improved patient days in both segments. However, higher expenses partially offset the positives.
OLDWICK, N.J., April 25, 2024--AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the key U.S. life/health subsidiaries and Europe-based insurance companies of The Cigna Group (Cigna) (headquartered in Bloomfield, CT) [NYSE: CI]. In addition, AM Best has affirmed the Long-Term ICR of "bbb+" (Good) and the Long-Term Issue Credit Ratings (Long-Term IRs) of Cigna. AM Best also has affirmed the Sho
BATON ROUGE, La., April 25, 2024--Humana Healthy Horizons commits $500,000 to improve the health of Louisianians.
Robust Performance Driven by Strong Acute and Behavioral Health Care Services
Walgreens is launching new services and consolidating specialty services to compete in the pharmacy benefits management (PBM) space.